Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Lucid Group Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Lucid Group Inc trades at $3.79 (market cap $1.51B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 4× Lucid Group Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Lucid Group Inc for 45 Days on average.
| IOVA | LCID | |
|---|---|---|
Market Cap | $6.04B | $1.51B |
Volume | 14,805,993 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $21.92 |
52-Week Low | $1.81 | $3.79 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $5.97B | $4.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lucid Group (LCID) trades at $3.82, down 1.8% with a bearish technical outlook. The company faces significant financial challenges with negative profit margins (-249.21% net income margin) and consecutive earnings misses. Recent developments include strategic partnerships for autonomous vehicles and software updates, but cash burn remains elevated at -$2.93B operating cash flow in 2025.
LCID presents high-risk turnaround potential with analyst consensus target of $7.60 (99% upside) but requires successful execution on cost savings and new vehicle launches. Key risks include persistent cash burn, production delays, and competitive EV market pressures. The stock's viability hinges on management's ability to achieve targeted $1.4B cost savings and deliver the delayed Cosmos SUV.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
